Navigation Links
Trianni Announces Launch of Its Optimized Human Antibody Transgenic Mouse
Date:9/26/2013

EMERYVILLE, Calif., Sept. 26, 2013 /PRNewswire/ -- Trianni, Inc., a Californian biotechnology company, announced today the launch of its Trianni Mouse, a monoclonal antibody discovery platform optimized for isolation of best-in-class therapeutic candidates.

Monoclonal antibodies are the most successful biologic therapeutics on the market.  More than thirty have been approved for use in humans and hundreds are currently undergoing testing in clinical trials for a broad range of clinical conditions.  Among the options currently available for therapeutic antibody discovery, transgenic mice, such as the Trianni Mouse, are unmatched in their suitability for meeting pharmaceutical research needs.

The Trianni Mouse is an advanced transgenic platform featuring highly engineered antibody genes, generated using state-of-the-art DNA synthesis and genome modification methodology.  It replicates the full antibody-producing capacity – or repertoire – of a human being, and features many enhancements designed to improve its performance as a discovery vehicle.  Trianni's technology represents a significant and highly distinctive advance over existing human antibody transgenic mouse platforms.

The Trianni Mouse platform is now available, with additional variations to follow in the first half of 2014.

Trianni is actively seeking partnerships with interested biotechnology and pharmaceutical companies.  For further information on the technology, please visit trianni.com.

About the Trianni Mouse Antibody Discovery Platform

Trianni took a radically different approach to generating its transgenic mouse platform.  This began with the design and chemical synthesis of novel chimeric antibody 'gene segments' each composed of human antibody-coding information combined directly with mouse regulatory information.  Well over a hundred distinct segments were assembled into large arrays, which were then embedded in the mouse genome in place of their normal mouse counterparts.  The outcome was antibody genes that are optimized for function in the mouse yet nonetheless express a full repertoire of human variable domains.  The Trianni mouse that carries these unique genes is a validated platform ideal for the isolation of therapeutic monoclonal antibodies.

About Trianni

Trianni was formed in 2010 with the sole focus of developing and distributing its optimized antibody discovery platform, The Trianni Mouse. It has been funded throughout from private sources. The company has administrative and research facilities in the San Francisco Bay Area and in Germany, respectively. Its executive team includes academic molecular immunologists and business development personnel with successful track records in biotechnology.

Contact:

Michael Greenberg, Chief Business Officer
Phone: +1 650-530-0640
Email: Michael.greenberg@trianni.com

 


'/>"/>
SOURCE Trianni
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
Breaking Medicine News(10 mins):